Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $675.31M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 1.66M
Average 1.66M
Returns on capital
Kura Oncology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-160.0%
avg -45.5%
ROIC
-48.8%
avg -33.7%
ROA
-37.7%
avg -29.5%
Analysis
ROA is currently the strongest return metric at -37.7% versus its period average of -29.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Troy Edward Wilson | Chairman, Chief Executive Officer & President | USD 1.44M | 57 | 479.19K | 0.54% |
Kathleen Ford | Chief Operating Officer | USD 926.5K | 79 | 142.99K | 0.16% |
Mollie Leoni | Chief Medical Officer | USD 855.3K | 48 | 141.09K | 0.16% |
Brian T. Powl | Chief Commercial Officer | USD 815K | 52 | 136.82K | 0.15% |
Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | USD 745.02K | 55 | 187.00K | 0.21% |
Francis J. Burrows | Chief Scientific Officer | — | 64 | — | — |
Jennifer Fulk | Chief Financial Officer | — | 49 | 0 | <0.01% |
Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | — | — | — | — |
Thomas Doyle | Senior Vice President of Finance & Accounting | — | 55 | — | — |
Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | — | — | — | — |
Samir Vattompadam | Senior Vice President of Global Program Leadership | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.35M
Sells
35
$3.34M
Net Transaction Value
−$992,944.74
Net selling
Most Active
Powl Brian T.
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 29, 26Sep 29, 2026 | Leoni Mollie Direct | Sell | $309.6K$309,566.78 |
| Sep 29, 26Sep 29, 2026 | FORD KATHLEEN Direct | Sell | $39.4K$39,436.87 |
| Sep 29, 26Sep 29, 2026 | Powl Brian T. Direct | Sell | $165.9K$165,852.44 |
| Sep 28, 26Sep 28, 2026 | DOYLE THOMAS JAMES Direct | Sell | $48.4K$48,360.60 |
| Sep 28, 26Sep 28, 2026 | Powl Brian T. Direct | Sell | $94.7K$94,685.65 |
| Sep 28, 26Sep 28, 2026 | Powl Brian T. Direct | Sell | $84.5K$84,497.60 |
| Sep 28, 26Sep 28, 2026 | FORD KATHLEEN Direct | Sell | $72.5K$72,494.35 |
| Sep 28, 26Sep 28, 2026 | Bair Teresa Brophy Direct | Sell | $88.6K$88,618.21 |
| Sep 28, 26Sep 28, 2026 | Leoni Mollie Direct | Sell | $130.7K$130,670.39 |
| Sep 24, 26Sep 24, 2026 | Burrows Francis Direct | Sell | $224.5K$224,514.40 |
1–10 of 37
Summary
Insiders reported 2 buys worth $2.35M and 35 sells worth $3.34M over the last 12 months. That adds up to net selling of $992,944.74. Powl Brian T. was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +66.5% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +66.5% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Kura Oncology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KURA's management, answered from reported figures.
Who manages KURA?
Kura Oncology, Inc. (KURA) lists 11 active executives. The top listed executive is Francis J. Burrows, Chief Scientific Officer.
Are KURA insiders buying or selling?
Recent insider activity shows net buying of $62.90M.
Continue the stock analysis
Jump to another research area for this company.